Literature DB >> 30815205

Learning When Communications Between Healthcare Providers Indicate Hormonal Therapy Medication Discontinuation.

Zhijun Yin1, Jeremy L Warner1, Bradley A Malin1.   

Abstract

Hormonal therapy is an effective yet challenging long-term treatment for patients with hormone receptor positive breast cancer. Understanding what factors indicate discontinuation of a recommended hormonal therapy medication can help improve treatment experience. To date, studies on medication discontinuation have focused on patient information gathered through questionnaires, structured electronic medical records and online discussion boards. However, there has been little investigation into the communications between healthcare providers, which may provide additional indicators of patients' medication discontinuation, particularly from a clinical perspective. In this paper, we investigate the relation between such communications and hormonal therapy medication discontinuation. We studied a cohort of 2,579 patients on hormonal therapy at the Vanderbilt University Medical Center over a 16-year period. We adopt a data-driven approach to investigate the clinical messages communicated by their healthcare providers, the messaging patterns, topics they communicated, and the extent to which these factors are affiliated with discontinuation to a recommended 5-year treatment protocol. Our findings suggest that notification of unread messages, plans for clinical trials and the occurrence of treatment-related complications are affiliated with an increased risk of medication discontinuation. By contrast, ordering prescriptions, making appointments, using positive communication verbs, and noting patients' stable health conditions are affiliated with a decreased risk of medication discontinuation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30815205      PMCID: PMC6371302     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  12 in total

1.  Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.

Authors:  Kathryn E Weaver; Fabian Camacho; Wenke Hwang; Roger Anderson; Gretchen Kimmick
Journal:  Am J Clin Oncol       Date:  2013-04       Impact factor: 2.339

2.  Talking About My Care: Detecting Mentions of Hormonal Therapy Adherence Behavior in an Online Breast Cancer Community.

Authors:  Zhijun Yin; Wei Xie; Bradley A Malin
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

3.  Development of a large-scale de-identified DNA biobank to enable personalized medicine.

Authors:  D M Roden; J M Pulley; M A Basford; G R Bernard; E W Clayton; J R Balser; D R Masys
Journal:  Clin Pharmacol Ther       Date:  2008-05-21       Impact factor: 6.875

Review 4.  Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.

Authors:  Rowan T Chlebowski; Jisang Kim; Reina Haque
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-17

5.  Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer.

Authors:  Alfred I Neugut; Milayna Subar; Elizabeth Ty Wilde; Scott Stratton; Corey H Brouse; Grace Clarke Hillyer; Victor R Grann; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 6.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.

Authors:  Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon
Journal:  Breast Cancer Res Treat       Date:  2012-06-12       Impact factor: 4.872

7.  Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.

Authors:  Sayaka Kuba; Mayumi Ishida; Yoshiaki Nakamura; Kenichi Taguchi; Shinji Ohno
Journal:  Breast Cancer       Date:  2014-06-17       Impact factor: 4.239

8.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.

Authors:  Betsy A Kohler; Recinda L Sherman; Nadia Howlader; Ahmedin Jemal; A Blythe Ryerson; Kevin A Henry; Francis P Boscoe; Kathleen A Cronin; Andrew Lake; Anne-Michelle Noone; S Jane Henley; Christie R Eheman; Robert N Anderson; Lynne Penberthy
Journal:  J Natl Cancer Inst       Date:  2015-03-30       Impact factor: 13.506

Review 9.  Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review.

Authors:  Zoe Moon; Rona Moss-Morris; Myra S Hunter; Sophie Carlisle; Lyndsay D Hughes
Journal:  Patient Prefer Adherence       Date:  2017-02-23       Impact factor: 2.711

10.  The challenge of patient adherence.

Authors:  Leslie R Martin; Summer L Williams; Kelly B Haskard; M Robin Dimatteo
Journal:  Ther Clin Risk Manag       Date:  2005-09       Impact factor: 2.423

View more
  2 in total

1.  Patient Messaging Content Associated with Initiating Hormonal Therapy after a Breast Cancer Diagnosis.

Authors:  Zhijun Yin; Jeremy L Warner; Qingxia Chen; Bradley A Malin
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

2.  Predicting Hormonal Therapy Medication Discontinuation for Breast Cancer Patients using Structured Data in Electronic Medical Records.

Authors:  Congning Ni; Jeremy L Warner; Bradley A Malin; Zhijun Yin
Journal:  AMIA Annu Symp Proc       Date:  2022-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.